"We're here to succeed together or fail together...We're not failing" (AT interview with Michael Frazis interview March 2025.) Since that interview the latest updates continue to reinforce the technical case of each current trial.
AT clearly is very astute. IMO there's no way he'd forestall the longer term outcome of the trials and development work, and ultimately maximisation of revenue, by prematurely negotiating a less than acceptable commercial deal. A commercial deal would need to be of an order of magnitude consistent with the market caps of those companies providing inferior diagnostic imaging products plus a significant portion of the therapy mkt (IMO)
CU6 Price at posting:
$2.53 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)